Validation of the PAGE-B score to predict hepatocellular carcinoma risk in caucasian chronic hepatitis B patients on treatment

Table 1 Demographic and follow-up characteristics of study population

	n = 742
Age, yr ± SE	45.0 ± 0.5
Gender, male n (%)	472 (63.6)
Follow-up, mo ± SE	54.7 ± 1.2
Diabetes mellitus, n (%)	116 (15.7)
HBeAg positivity, n (%)	171 (23.0)
Cirrhosis, n (%)	161 (21.7)
NA(s) before ETV/TDF, n (%)	162 (21.8)
Antiviral treatment (ETV/TDF), n (%)	240 (32.3)/502(67.7)
MVR, n (%)	633 (85.3)
Hepatic flare, n (%)	25 (3.4)
ALT normalization at 6 mo, n (%)	620 (85.9)
Virological response at 6 mo, n (%)	597 (85.4)
PAGE-B score ± SE	11.1 ± 0.2
PAGE-B score-risk groups, n (%)
Low	281 (37.9)
Moderate	341 (46)
High	120 (16.2)
HCC cases during follow up, n (%)	26 (3.5)

HBeAg: Hepatitis B e antigen; ALT: Alanine transaminase; ETV: Entecavir; HCC: Hepatocellular carcinoma; MVR: Maintained virological response; NA(s): Nucleos(t)ide analogue(s); TDF: Tenofovir disoproxil fumarate; SE: Standard error of mean.